Evidence map›Paper›PMID 15539501›Full record

ArticleClinical and diagnostic laboratory immunology2004

Diagnosis of norwalk virus infection by indirect enzyme immunoassay detection of salivary antibodies to recombinant norwalk virus antigen.

Christine L Moe, Arnie Sair, Lisa Lindesmith, Mary K Estes, Lee-Ann Jaykus

Open access · diamondAbstract read
In one paragraph

Article in Clinical and diagnostic laboratory immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2017
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Christine L MoeDepartment of International Health, Rollins School of Public Health of Emory University, 1518 Clifton Rd. NE, Room 716, Atlanta, GA 30322, USA. clmoe@sph.emory.edu
Arnie Sair
Lisa Lindesmith
Mary K Estes
Lee-Ann Jaykus
North Carolina State University · USUniversity of North Carolina at Chapel Hill · USBaylor College of Medicine · US

Funding

Zonisamide in Patients with Neuropathic Pain Associated with Diabetic NeuropathyM01RR000046 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOY, MELANIE S · 1985 to 2008
$38.5M
X-ray Crystallographic Studies on CalicivirusesP01AI057788 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI ATMAR, ROBERT L., ESTES, MARY KOLB · 2004 to 2024
$34.4M
ENTERIC PATHOGENS - MUCOSAL RESEARCH UNIT-266965299N01AI065299 · NIAID · UNIVERSITY OF MARYLAND BALT PR · 1996 to 2003
$1.0M
NCRR NIH HHS M01 RR000046NCRR NIH HHS RR00046NIAID NIH HHS AI 57788NIAID NIH HHS AI 65299NIAID NIH HHS N01 AI065299NIAID NIH HHS P01 AI057788
6 · The paper itself

Abstract

Simple diagnostic tests are needed for the detection of norovirus (NoV) outbreaks. Salivary antibody assays provide an attractive alternative to collecting and testing serum or stool samples. Antibodies to Norwalk virus (NV) in oral fluid samples were compared with NV antibodies in serum collected from 38 volunteers challenged with NV inoculum. Pre- and postchallenge (day 4, 8, 14, and 21) saliva and serum samples were examined by enzyme immunoassay (EIA) using recombinant NV antigen. Of 18 infected subjects (those who shed NV in stool or who demonstrated immunoglobulin G [IgG] seroconversion), 15 (83%) had > or =4-fold increases in NV-specific salivary IgA and 15 (83%) had > or =4-fold increases in NV-specific salivary IgG when prechallenge and postchallenge saliva samples were compared. When the results of the IgA and IgG assays were combined, all 18 infected subjects showed > or =4-fold increases in NV-specific salivary IgG or IgA postchallenge titers compared to their prechallenge titers. One of 19 uninfected subjects had a > or =4-fold increase in NV-specific salivary IgG. The sensitivity of the combined assay results was 100%, and the specificity was 95%. NV-specific salivary IgA titers peaked around 14 days postchallenge. NV-specific salivary IgG and serum IgG titers continued to rise through 21 days postchallenge. The application of this EIA to an elementary school outbreak indicated that 67% of the subjects with confirmed infections had >4-fold rises in anti-NoV IgA when an antigen in the same genetic cluster as the outbreak virus was used. This is the first documented mucosal antibody response to NoV in children. This EIA provides a useful approach for diagnosing NoV outbreaks.

Indexed as

AdultAntibodies, ViralCaliciviridae InfectionsCapsid ProteinsEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin AImmunoglobulin GMaleNorwalk virusPredictive Value of TestsSalivaAntibodies, ViralCapsid ProteinsImmunoglobulin AImmunoglobulin GNorwalk virus capsid

Identifiers

PMID15539501
PMCPMC524746
OpenAlexW2146013517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.